Your browser is no longer supported. Please, upgrade your browser.
COGT Cogent Biosciences, Inc. daily Stock Chart
Cogent Biosciences, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own0.20% Shs Outstand31.11M Perf Week11.74%
Market Cap122.57M Forward P/E- EPS next Y-0.19 Insider Trans- Shs Float26.99M Perf Month-6.12%
Income-23.10M PEG- EPS next Q-0.14 Inst Own65.50% Short Float2.84% Perf Quarter-4.83%
Sales23.90M P/S5.13 EPS this Y24.70% Inst Trans105.54% Short Ratio1.37 Perf Half Y626.51%
Book/sh0.62 P/B4.45 EPS next Y56.80% ROA-52.10% Target Price- Perf Year85.23%
Cash/sh- P/C- EPS next 5Y- ROE-87.80% 52W Range0.29 - 3.72 Perf YTD283.23%
Dividend- P/FCF- EPS past 5Y- ROI-101.20% 52W High-25.67% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low837.29% ATR0.30
Employees72 Current Ratio2.90 Sales Q/Q-83.90% Oper. Margin-98.10% RSI (14)53.21 Volatility14.21% 12.35%
OptionableNo Debt/Eq0.00 EPS Q/Q31.10% Profit Margin-96.80% Rel Volume0.49 Prev Close2.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume557.75K Price2.77
Recom1.00 SMA209.92% SMA506.32% SMA200103.89% Volume258,332 Change0.18%
Oct-14-20Initiated Ladenburg Thalmann Buy $4
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a A'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.